| |
 |
|
|
Science Forum Index » Life Extension Forum » A419C (E111A) Polymorphism of the Glyoxalase I Gene...
Page 1 of 1
|
| Author |
Message |
| Olafur Pall Olafsson... |
 Posted: Sun May 04, 2008 2:13 pm |
|
|
|
Guest
|
Glyoxalase I is a glutathione-binding protein involved in the
detoxification of methylglyoxal a byproduct of glycolysis. In the
study below patients homozygous for the mutated (CC) allele had higher
sRAGE levels (reflecting a higher AGE burden) compared to patients
with the AA and AC allele combinations. Patients with the CC allele
also had higher prevalence of cardiovascular disease and peripheral
vascular disease. This lends further support to the notion that
enhancing glyoxalase I will be beneficial to prevent against glycation
related damage and for life-extension.
Unfortunately I am not aware of any mechanism to enhance the activity
of glyoxalase I. However it is known that the glyoxalase system
requires reduced glutathione (GSH) as a rate-limiting cofactor (PMID:
14641072). Therefore taking supplement that may help maintain high
levels of GSH in the body (such as R-alpha lipoic acid, NAC, L-
cysteine and whey protein) may be helpful in maximizing the activity
of glyoxalase I.
Ann N Y Acad Sci. 2008 Apr;1126:268-71. Epub 2007 Dec 13.
Related Articles, Links
Click here to read
A419C (E111A) Polymorphism of the Glyoxalase I Gene and Vascular
Complications in Chronic Hemodialysis Patients.
Kalousová M, Germanová A, Jáchymová M, Mestek O, Tesav V, Zima T..
Institute of Clinical Chemistry and Laboratory Diagnostics, 1
Faculty of Medicine and General University Hospital, Charles
University, Karlovo nám. 32, 121 11 Prague 2, Czech Republic.
marta.kalousova at (no spam) seznam.cz.
Advanced glycation end products (AGEs) take part in the
pathogenesis of vascular, diabetic, and uremic complications. Their
precursors are detoxified by the glyoxalase system. Our aim was to
study A419C (E111A) single nucleotide polymorphism (SNP) of the
glyoxalase I gene in hemodialysis (HD) patients. A419C SNP, several
laboratory parameters including soluble receptor for AGEs (sRAGE), and
clinical data were studied in 214 HD patients and 89 controls. Allelic
and genotypic frequencies did not differ between HD patients and
controls. A419C SNP was significantly linked with serum sRAGE, which
sensitively reflects the AGE burden of the organism (3986 +/- 1638 pg/
mL in the CC variant versus 3277 +/- 1398 pg/mL in the AC variant and
3297 +/- 1445 pg/mL in the AA variant, P < 0.01). In the CC variant,
significantly higher prevalence of cardiovascular disease and
peripheral vascular disease was found, while the prevalence of
hypertension, diabetes mellitus, and dyslipidemia did not differ
between genotypes. In summary, in this study we demonstrate for the
first time the association of A419C polymorphism of the glyoxalase I
gene with sRAGE levels and show the genetic predisposition to vascular
complications in HD patients.
PMID: 18079478 [PubMed - in process]
Related Articles
* Receptor for advanced glycation end products--soluble form
and gene polymorphisms in chronic haemodialysis patients. [Nephrol
Dial Transplant. 2007]
* Glyoxalase I deficiency is associated with an unusual level
of advanced glycation end products in a hemodialysis patient. [Kidney
Int. 2001]
* Association between serum levels of soluble receptor for
advanced glycation end products and circulating advanced glycation end
products in type 2 diabetes. [Diabetologia. 2006]
* Soluble receptor for advanced glycation end products in
patients with decreased renal function. [Am J Kidney Dis. 2006]
* Association of the Gly82Ser polymorphism in the receptor for
advanced glycation end products (RAGE) gene with circulating levels of
soluble RAGE and inflammatory markers in nondiabetic and nonobese
Koreans. [Metabolism. 2007]
* » See all Related Articles...
Display Show
* Write to the Help Desk |
|
|
| Back to top |
|
| |
|
Page 1 of 1
All times are GMT - 5 Hours
The time now is Wed Aug 20, 2008 6:05 am
|
|